Cidara Therapeutics Inc (CDTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Jeffrey L. Stein
Employees:
90
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121
858-752-6170

Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of long-acting anti-infectives. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis.

Data derived from most recent annual or quarterly report
Market Cap 83.077 Million Shares Outstanding71.618 Million Avg 30-day Volume 5.462 Million
P/E Ratio0.0 Dividend Yield0.0 EPS0.17
Price to Revenue0.9077 Debt to Equity0.0 EBITDA-32.589 Million
Price to Book Value6.1361 Operating Margin-54.1994 Enterprise Value2.558 Million
Current Ratio1.934 EPS Growth0.509 Quick Ratio1.759
1 Yr BETA 0.3168 52-week High/Low 2.1 / 0.4 Profit Margin-54.206
Operating Cash Flow Growth-4.3118 Altman Z-Score-7.8333 Free Cash Flow to Firm -17.007 Million
View SEC Filings from CDTX instead.

View recent insider trading info

Cidara Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CDTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CDTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-27 by TARI LESLIE
  • 4: filed on 2022-09-19 by SHAH PREETAM
  • 4: filed on 2022-09-13 by SANDISON TAYLOR
  • 4: filed on 2022-09-13 by TARI LESLIE
  • 4: filed on 2022-09-13 by DARUWALA PAUL
  • 4: filed on 2022-06-24 by FRANSON TIMOTHY R
  • 4: filed on 2022-06-24 by BURGESS DANIEL D
  • 4: filed on 2022-06-24 by BASSLER BONNIE L
  • 4: filed on 2022-06-24 by SCHROEDER THEODORE R
  • 4: filed on 2022-06-24 by MINEO CHRYSA

    • Events (8k)

  • 8-K: filed on 2023-03-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-01:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-21:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-02:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    25.7 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WARD SHANE COO & CLO

    • Officer
    		 84,576 2023-03-13 2

    SANDISON TAYLOR CHIEF MEDICAL OFFICER

    • Officer
    		 288,550 2023-03-13 3

    SHAH PREETAM CFO & CBO

    • Officer
    		 148,141 2023-03-13 3

    TARI LESLIE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 191,663 2023-03-13 4

    DARUWALA PAUL CHIEF OPERATING OFFICER

    • Officer
    		 221,099 2022-09-12 2

    BURGESS DANIEL D

    • Director
    		 28,000 2022-06-22 1

    SCHROEDER THEODORE R

    • Director
    		 28,000 2022-06-22 1

    FRANSON TIMOTHY R

    • Director
    		 28,000 2022-06-22 1

    MINEO CHRYSA

    • Director
    		 28,000 2022-06-22 1

    BASSLER BONNIE L

    • Director
    		 28,000 2022-06-22 1

    GOLLAHER DAVID L

    • Director
    		 28,000 2022-06-22 1

    CANALE-THEAKSTON CARIN

    • Director
    		 28,000 2022-06-22 1

    STEIN JEFFREY PRESIDENT & CEO

    • Officer
    • Director
    		 1,526,246 2022-03-31 1

    JOHNSON BRADY VICE PRESIDENT, FINANCE

    • Officer
    		 79,366 2022-03-31 1

    LEVINE JAMES E. CHIEF FINANCIAL OFFICER

    • Officer
    		 119,803 2021-03-17 0

    ABDOLLAHIAN NEIL CHIEF BUSINESS OFFICER

    • Officer
    		 208,308 2021-03-17 0

    OIEN JESSICA GENERAL COUNSEL & SECRETARY

    • Officer
    		 135,000 2021-03-17 0

    MUNDIPHARMA AG

    • 10% Owner
    		 4,781,408 2019-09-03 0

    ROCKLAGE SCOTT M

    • Director
    		 0 2018-06-13 0

    ONAITIS MATTHEW GNRL COUNSEL, CFO & SECRETARY

    • Officer
    		 0 2018-03-29 0

    BIOTECH TARGET N V

    BB BIOTECH AG

    • 10% Owner
    		 2,295,272 2017-11-15 0

    WILSON MARC CHIEF ACCOUNTING OFFICER

    • Officer
    		 10,356 2017-09-18 0

    PEREZ ROBERT J

    • Director
    		 0 2017-06-22 0

    BARTIZAL KEN CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2017-03-31 0

    FORREST KEVIN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 132,354 2017-03-31 0

    THYE DIRK CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-03-16 0

    ROCKLAGE SCOTT M

    5AM CO-INVESTORS III, L.P.

    5AM VENTURES III, L.P.

    DIEKMAN JOHN D

    SCHWAB ANDREW J.

    • Director
    • 10% Owner
    		 2,006,511 2015-04-20 0

    ELMS STEVE

    • Director
    		 1,054,610 2015-04-20 0

    HERON PATRICK J

    • Director
    		 No longer subject to file 2015-04-20 0

    KJELLSON NINA S

    • Director
    		 No longer subject to file 2015-04-20 0

    AISLING CAPITAL II LP

    AISLING CAPITAL PARTNERS, LP

    AISLING CAPITAL PARTNERS LLC

    SCHIFF ANDREW N

    PURCELL DENNIS J

    SEACHAID PHARMACEUTICALS, INC.

    • 10% Owner
    		 703,092 2015-04-14 0

    JUDICE KEVIN

    • Director
    		 94,488 2015-04-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SANDISON TAYLOR - Officer CHIEF MEDICAL OFFICER

    		2023-03-13 21:19:53 -0400 2023-03-13 S 7,203 $1.53 d 288,550 direct -1.1765 16.4706 16.4706 6 -4.1176 3

    SHAH PREETAM - Officer CFO & CBO

    		2023-03-13 21:20:50 -0400 2023-03-13 S 6,648 $1.53 d 148,141 direct -1.1765 16.4706 16.4706 6 -4.1176 3

    TARI LESLIE - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-13 21:21:27 -0400 2023-03-13 S 7,562 $1.53 d 190,179 direct -1.1765 16.4706 16.4706 6 -4.1176 3

    WARD SHANE - Officer COO & CLO

    		2023-03-13 21:21:56 -0400 2023-03-13 S 4,329 $1.53 d 84,576 direct -1.1765 16.4706 16.4706 6 -4.1176 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 22:15:03 UTC 3.1111 1.7089 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 21:45:03 UTC 3.1201 1.6999 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 21:15:03 UTC 3.1201 1.6999 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 20:45:03 UTC 3.1252 1.6948 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 20:15:04 UTC 3.1252 1.6948 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 19:45:03 UTC 3.1252 1.6948 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 19:15:04 UTC 3.1252 1.6948 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 18:45:04 UTC 3.7619 1.0581 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 18:15:03 UTC 3.7619 1.0581 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 17:45:03 UTC 3.7619 1.0581 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 17:15:03 UTC 3.7619 1.0581 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 16:45:03 UTC 3.6813 1.1387 500000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 16:15:03 UTC 3.6813 1.1387 600000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 15:45:03 UTC 3.6813 1.1387 600000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 15:15:03 UTC 3.6813 1.1387 600000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 14:45:03 UTC 3.6813 1.1387 600000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 14:15:03 UTC 3.6813 1.1387 650000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 13:45:03 UTC 3.4883 1.0817 650000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 13:15:04 UTC 3.4883 1.0817 650000
    CIDARA THERAPEUTICS INC CDTX 2023-03-24 12:45:03 UTC 3.4883 1.0817 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments